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A B S T R A C T
Purpose: Analysis of overall tolerability and neurological adverse effects (AEs) of eslicarbazepine acetate
(ESL), lacosamide (LCM) and oxcarbazepine (OXC) from double-blind, placebo-controlled trials. Indirect
comparisons of patients withdrawing because of AEs, and the incidence of some vestibulocerebellar AEs
between these three antiepileptic dugs (AEDs).
Methods: We searched MEDLINE for all randomized, double-blind, placebo-controlled trials investigat-
ing therapeutic effects of ﬁxed oral doses of ESL, LCM and OXC in patients with drug resistant epilepsy.
Withdrawal rate due to AEs, percentages of patients with serious AEs, and the proportion of patients
experiencing any neurological AE, nausea and vomiting were assessed for their association with the
experimental drug.
Analyses were performed between recommended daily doses of each AED according to the approved
summary of product characteristics (SPC). Risk differences were used to evaluate the association of any
AE [99% conﬁdence intervals (CIs)] or study withdrawals because of AEs (95% CIs) with the experimental
drug. Indirect comparisons between withdrawal rate and AEs dizziness, coordination abnormal/ataxia
and diplopia were estimated according to network meta-analysis (Net-MA).
Results: Eight randomized, placebo-controlled, double-blind trials (4 with ESL, 3 with LCM, and 1 with
OXC) were included in our analysis.
At high doses (OXC 1200 mg, ESL 1200 mg and LCM 400 mg) there was an increased risk of AE-related
study withdrawals compared to placebo for all drugs. Several AEs were associated with the experimental
drug. Both number and frequency of AEs were dose-related.
At high recommended doses, patients treated with OXC withdrew from the experimental treatment
signiﬁcantly more frequently than patients treated with ESL and LCM. Furthermore, the AEs coordination
abnormal/ataxia and diplopia were signiﬁcantly more frequently observed in patients treated with OXC
compared to patients treated with LCM and ESL.
Conclusions: The overall tolerability of AEDs and the incidence of several neurological AEs were clearly
dose-dependent. Indirect comparisons between these AEDs, taking into account dose-effect, showed
that OXC may be associated with more frequent neurological AEs than LCM and ESL.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Neurological adverse events (AEs) are frequently observed in
patients treated with antiepileptic drugs (AEDs) and are often
responsible of treatment failure and poor quality of life.1,2 Amongst* Corresponding author at: Unit of Neurology, San Giovanni di Dio Hospital, Via Di
Torregalli 3, Azienda Sanitaria di Firenze, 50143 Firenze, Italy.
Tel.: +39 055 7192476; fax: +39 055 7192280.
E-mail addresses: gaetano.zaccara@asf.toscana.it, gaetanozaccara@yahoo.it
(G. Zaccara).
1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.03.016these AEs, the most common is sedation, which is observed with
almost all AEDs, and brain stem, and vestibulocerebellar AEs,
which are most often observed with voltage-gated sodium
channels (VGSC) blocker AEDs.3
Vestibulocerebellar AEs may be characterized by objective
involvement of gait and motor coordination (which in clinical trials
are named ataxia, unsteadiness, abnormal gait, balance distur-
bance, imbalance, coordination disturbance)4 or by subjective
signs such as dizziness or vertigo. Other signs expression of brain
stem involvement are those affecting ocular motor functions such
as diplopia, blurred vision, and nystagmus.3vier Ltd. All rights reserved.
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neurological tolerability proﬁle of oxcarbazepine (OXC) and two
other recently approved VGSC blockers AEDs – lacosamide (LCM)
and eslicarbazepine acetate (ESL) – at their recommended daily
dosages for the adjunctive treatment of partial-onset seizures
(POS) in adults, based on data from phase III clinical studies
performed with each drug in this patient population.
2. Methods
2.1. Criteria for considering studies for this review
We included randomized, double-blinded, placebo-controlled
trials investigating therapeutic effects of ﬁxed doses of oral ESL,
LCM and OXC as adjunctive therapy of POS in adults. Full journal
publication was required, with brief abstracts not included. All
other types of studies, including non-randomized trials, case
reports, or clinical observations, were excluded.
We focused this meta-analysis on adjunctive treatment of POS,
since tolerability of these drugs in patients with other diseases
than epilepsy and as monotherapy is different from that observed
in drug resistant epileptic patients.5,6
We searched in PubMed oxcarbazepine OR Trileptal, lacosa-
mide OR Vimpat and eslicarbazepine acetate OR Zebinix with
limits: ‘‘Randomized controlled trial (or Clinical trial)’’ and
‘‘Humans’’. Additional studies were sought in reference lists of
retrieved articles and in The National Institutes of Health (NIH)
clinical trial registry (www.clinicaltrial.gov). Eligibility was
determined after reading each study identiﬁed by our search.
All studies were read independently by two authors (G.Z. and A.V.)
and agreement for inclusion/exclusion was reached after
discussion
2.2. Comparison between recommended therapeutic dosages
Since neurological AEs are dose-dependent,3,7,8 we considered
that tolerability proﬁle of the AEDs under analysis should be
performed at equi-effective dosages. However, equally effective
dosages are not available in the literature and therefore we decided
to compare the tolerability proﬁles taking mainly into account the
recommended daily dosages of each agent for the treatment of POS
in adults, based on the approved summary of product character-
istics (SPC).9–13
For the purpose of comparisons performed in this meta-analysis
we have set the minimum effective recommended daily dosages to
be OXC 600 mg, ESL 800 mg, and LCM 200 mg; the highest effective
recommended daily dosage was set as OXC 1200 mg, ESL 1200 mg,
and LCM 400 mg. Separate analyses per dose were performed (each
dose arm was compared with placebo arm).
2.3. Outcome measures
Our primary outcome of interest was identiﬁcation of speciﬁc
neurological AEs and our secondary outcome was the comparison
of percentages of patients withdrawing due to any AE. However,
the secondary outcome will be discussed ﬁrst.
2.3.1. Withdrawal rate due to AEs
We calculated placebo-subtracted percentages of patients
withdrawing because of AEs. In a second step, we made an
indirect comparison of placebo-subtracted percentages of patients
withdrawing because of AEs.
2.3.2. Proportion of patients experiencing neurological AEs
We identiﬁed all neurological AEs signiﬁcantly associated with
the experimental drug in double-blinded studies with these AEDs.We included nausea and vomiting as neurological AEs because at
least in some cases they are a consequence of neurological toxicity.
We also performed an indirect comparison of placebo-subtracted
percentages of three out of the most important AEs caused by
vestibulocerebellar involvement: dizziness, coordination abnor-
mal (or ataxia), and diplopia between these three AEDs.
These analyses were performed after the identiﬁcation of
synonyms – grouped under one main term – and the exclusion of
rare AEs (i.e. those AEs observed in <5 patients among those
randomized to the experimental drug or placebo).
2.4. Statistical analysis
Statistical heterogeneity was assessed using the I2 test, with an
I2 > 70% indicating heterogeneity.14 Provided that no signiﬁcant
heterogeneity was detected (I2 < 70%), analyses were carried out
using a ﬁxed-effect model. When I2 was >70%, a random-effect
model was used.
Risk differences (RDs) were used to estimate withdrawal rate
and to identify AEs signiﬁcantly associated with the experimental
drug. A 95% conﬁdence interval (CI) was used for the analysis of
withdrawal rate and 99% (CI) for the analysis of AEs. In the last
case, this conservative approach was aimed at minimizing the
error rate.
All analyses were carried out with RevMan version 5.1.15
The statistical models for the indirect comparisons were based
on the frequentist model described by Bucher and colleagues.16 No
heterogeneity was assessed for indirect comparisons; this assess-
ment was restricted to direct comparisons (see I2 test).
The RD (with 95% CI) for each indirect comparison was
estimated according to the ITC software (Canadian Agency for
Drugs and Technologies in Health, Indirect Treatment Comparison
software, Ottawa, Ontario, Canada). This approach allows an
indirect RD (with 95% CI) to be estimated upon the condition that
both treatments included in the indirect comparison have been
compared in actual trials against a common comparator (which in
our case was placebo). Graphs were plotted using GRNETMA.EXE
software (Societa` Italiana di Farmacia Ospedaliera, Milan, Italy)
(www.osservatorioinnovazione.org).17
3. Results
3.1. Description of studies
3.1.1. Studies search results
A total of 95 references were identiﬁed through electronic
databases searches (see Appendix 1). From this initial sample, we
excluded non double-blinded studies, abstracts, active compara-
tor-controlled studies, studies in which these drugs were
administered intravenously, studies performed on children,
healthy volunteers, or for indications other than epilepsy. Eight
randomized, placebo-controlled, double-blind trials (1 with OXC, 3
with LCM and 4 with ESL) were carefully evaluated and included in
our analysis (Table 1). For a detailed description of included studies
see Appendix 2.
3.1.2. Characteristics of studies
The 8 studies included a total of 2732 subjects, 1858 of whom
were randomized to active drug and 874 to placebo (Table 1). In all
studies, patients received placebo or were titrated to a ﬁxed dose
regimen of the experimental drug.
In the 4 studies performed with ESL, 855 subjects were treated
with active drug and 337 with placebo. Nine hundred-forty-four
subjects were treated with LCM and 364 with placebo in the 3 LCM
study. Finally, 519 subjects were treated with OXC and 173 with
placebo in the OXC study.
Table 1
Double-blind studies performed with eslicarbazepine acetate, lacosamide and oxcarbazepine in patients with drug-resistant partial epilepsies.
Author AEDs allowed (n) Titration speed Study duration
(weeks)
Placebo (n) Daily dose of the experimental drug
400 mg/d (n) 800 mg/d (n) 1200 mg/d (n)
Double-blind studies performed with eslicarbazepine acetate
Ben-Menachem et al., 201018 1–3 Starting dose: 400 mg or
800 mg/d. Pts randomized
to 1200 mg/d achieved
ﬁnal dose within 2 wks
14 100 96 100 97
Elger et al., 200719 1–2 Starting dose:400 mg/d.
Final dose achieved
within 4 wks
12 47 – – 97a
Elger et al., 200920 1–2 Starting dose:400 mg/d.
Dose increments of
400 mg/d each week
12 102 100 98 102
Gil-Nagel, 200921 1–2 Starting dose: 400 mg/d.
Final dose achieved
within 2 wks
14 88 – 85 80
Total 337 196 283 376
Author AEDs allowed (n) Titration speed Study duration
(weeks)
Placebo (n) Daily dose of the experimental drug
200 mg/d (n) 400 mg/d (n) 600 mg/d (n)
Double-blind studies performed with lacosamide
Ben-Menachem et al., 200722 1–2 Starting dose100mg/d.
Weekly increments of
100 mg up to the ﬁnal dose
12 97 107 108 106
Chung et al., 201023 1–3 Starting dose100mg/d.
Weekly increments of
100 mg up to the ﬁnal dose
18 104 – 204 97
Hala`sz et al., 200924 1–3 Starting dose100mg/d.
Weekly increments of
100 mg up to the ﬁnal dose
16 163 163 159 –
Total 364 270 471 203
Author AEDs allowed (n) Titration speed Study duration
(weeks)
Placebo (n) Daily dose of the experimental drug
600 mg/d
(n)
1200 mg/d (n) 2400/d (n)
Double-blind studies performed with oxcarbazepine
bBarcs et al., 200025 1–3 Six-hundred mg achieved
within 2 days, 1200 mg/d
achieved within 6 days, 2
400 mg/d achieved
within 14 days
28 (2 + 24 + 2) 173 168 177 174
a QD and BID.
b During the study, since a large number of patients were discontinued because of AEs, a protocol amendment was prepared to allow for a blinded reduction to 1800 mg/d in
the 2400 mg/d OXC treatment group either directly after randomization or on the occurrence of AEs. Forty-seven of the 174 patients randomized to 2400 mg/d were treated
with a 1800 mg/d drug dose.
Fig. 1. Patients withdrawing because of adverse events in clinical studies with
eslicarbazepine acetate, lacosamide and oxcarbazepine at low and high doses as
reported in the SPC (for details, see text).
G. Zaccara et al. / Seizure 22 (2013) 528–536530ESL was studied at 400 mg/day (two studies), 800 mg/day (3
studies) and 1200 mg/day (4 studies). LCM was studied at
200 mg/day (2 studies), 400 mg/day (3 studies), and 600 mg/day
(2 studies). OXC was studied at 600 mg/day, 1200 mg/day and
2400 mg/day. All studies included patients with POS and treated
with other AEDs. In all cases, efﬁcacy and safety assessments
were performed on patients who received at least one dose of
drug.
In ESL studies, the experimental drug was started with a dose of
400 mg or 800 mg once daily and dose increments to 1200 mg/day
were performed after one week or more slowly. LCM was started at
100 mg/daily dose with weekly increments to the ﬁnal dose in all
cases. In the study with OXC, drug dose was increased to 600 mg/
day within 2 days and to 1200 mg/day within 6 days. A further
increase to 2400 mg/day (or 1800 mg/day after a protocol
amendment) was done after 2 weeks.
Risk of bias as regards incomplete reporting of outcome
data (attrition bias), and selective reporting was considered
low in all studies. Random sequence generation was described
in all studies but three,18,21,24 while was not given information
on selection, performance, and detection bias in any of the
studies.
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3.2.1. Withdrawal rate due to AEs
Heterogeneity (I2 > 70%) was found with ESL at all doses and
with LCM at 200 mg/d dose and in these cases a random model was
adopted. In all other cases a ﬁxed-effect model was used. High
heterogeneity in ESL studies was mainly due to higher reporting in
Ben-Menachem et al. study.18
At higher effective recommended daily dosage there was an
increased risk of AE-related study withdrawals compared to
placebo for all drugs. (see Fig. 1).
3.2.2. Proportion of patients experiencing neurological AEs
In the 4 studies with ESL, we found 18 AEs. Eleven were
neurological. Amongst them, drowsiness was considered as
synonymous of somnolence and merged with this AE. Convulsion,Fig. 2. Neurological adverse events observed in clinical studies with eslicarbazepine acet
details, see text).concentration impaired and insomnia were observed in less than 5
subjects and excluded from further analysis.
Seventeen AEs were observed in the 3 studies with LCM, nine of
whom were considered neurological. Coordination abnormal was
reported in 2 studies22,23 while ataxia was only reported in one.22
These AEs were considered as synonymous and merged as
coordination abnormal/ataxia.
Fifteen AEs were reported in the OXC study and 10 were
considered neurological. Abnormal gait and ataxia were consid-
ered as synonymous of coordination abnormal and merged as
coordination abnormal/ataxia. For a detailed description of all
neurological AEs, see Appendix 3.
3.2.3. Meta-analysis of neurological AEs observed in ESL studies
Evidence of heterogeneity (I2 > 70%) was found for coordina-
tion abnormal, diplopia and vomiting at the dose of 800 mg/dayate, lacosamide and oxcarbazepine at low and high doses as reported in the SPC (for
Table 2
Indirect comparisons of neurological AEs dizziness, ataxia/coordination abnormal,
and diplopia between eslicarbazepine acetate, lacosamide and oxcarbazepine (RD
(95% IC) at minimum recommended dosage (ESL: 800 mg/day, LCM 200 mg/day and
OXC 600 mg/day) as reported in the SPC (for details, see text).
Dizziness
ESL vs LCMt 0.05 [0.024, 0.124]
LCMt vs OXC 0.03 [0.129, 0.069]
ESL vs OXCt 0.02 [0.081, 0.121]
Ataxia/coordination abnormal
ESL vs LCMt 0.01 [0.074, 0.094]
LCMt vs OXC 0.06 [0.13, 0.01]
ESLt vs OXC 0.05 [0.153, 0.053]
Diplopia
ESL vs LCMt 0.01 [0.08, 0.1]
LCMt vs OXC 0.04 [0.107, 0.027]
ESLt vs OXC 0.03 [0.134, 0.074]
For explanations, see text.
t Treatment is favored by a trend in cases of no signiﬁcant difference.
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to a trend for higher percentage of patients with these AEs in one18
study and lower reporting in two19,21 and in these cases a random
effect model was adopted. In all other cases, a ﬁxed-effect model
was used.
Dizziness at 800 mg/day, and diplopia and nausea at 1200 mg/
day were signiﬁcantly associated with the experimental drug (see
Fig. 2 and Appendix 4).
3.2.4. Meta-analysis of neurological AEs observed in LCM studies
Heterogeneity (I2 > 70%) was observed for dizziness at 400 mg/
day and in that case a random effect model was used. This was
caused by higher reporting in one study.22 In all other cases, a
ﬁxed-effect model was used.
At 200 mg/day, dizziness was signiﬁcantly associated with
LCM. At 400 mg/day AEs associated with the experimental drug
were ﬁve, i.e. dizziness, ataxia/coordination abnormal, diplopia,
nausea, and vomiting. (Fig. 2 and Appendix 4).
3.2.5. Meta-analysis of neurological AEs observed in OXC study
Three AEs (dizziness diplopia and vomiting) were signiﬁcantly
associated with the experimental drug at 600 mg daily dose. Eight
AEs (somnolence, dizziness, vertigo, ataxia/coordination abnormal,
diplopia, nystagmus, nausea and vomiting) were associated with a
drug daily dose of 1200 mg (Fig. 2 and Appendix 4).
3.2.6. Indirect comparison of withdrawal rates due to AEs, and of
proportion of patients experiencing neurological AEs
An indirect comparison of RDs (95% IC) of patients withdrawing
because of AEs and of patients complaining of dizziness, coordina-
tion abnormal/ataxia and diplopia, was performed. At the minimum
recommended daily dosages, indirect comparisons failed to
evidence any signiﬁcant difference between the three AEDs even
though a non-signiﬁcant trend favored OXC and LCM in the indirect
comparison between LCM and ESL. (Patients withdrawing becauseFig. 3. Patients withdrawing because of AEs in clinical studies with eslicarbazepine ac
recommended dosages (ESL: 1200 mg/day, LCM 400 mg/day and OXC 1200 mg/day) as 
indirect comparison by a dotted line. Statistical results of event rate ratio are presented as
for direct and indirect comparisons were calculated according to the REVMAN and the ITC
statistical signiﬁcance, and vice versa for ‘’; ‘=’ denotes comparisons showing no signi
signiﬁcant difference.of AEs: LCM vs OXC: 0.02 (0.091, 0.131); ESL vs OXC: 0.04 (0.063,
0.143); ESL vs LCM: 0.02 (0.1, 0.14). See Table 2.
At high recommended doses it is shown that patients treated
with OXC withdrew from the experimental treatment signiﬁcantly
more frequently than patients treated with ESL and LCM while
between ESL and LCM, there was a non-signiﬁcant trend in favor of
ESL (Fig. 3).
The AEs coordination abnormal/ataxia and diplopia were
signiﬁcantly more frequently observed in patients treated with
OXC compared to patients treated with LCM and ESL. Between ESL
and LCM there was a non signiﬁcant trend in favor of ESL. A non
signiﬁcant trend, always favoring LCM and ESL against OXC and ESL
against LCM, was observed for the AE dizziness (Fig. 4).
This analysis was complemented by the computation of the
number needed-to-harm (NNH) for dizziness, coordination abnor-
mal/ataxia and diplopia associated with ESL, LCM, and OXC at highetate, lacosamide and oxcarbazepine. Indirect comparison (RD (95% IC)) at higher
reported in the SPC. Each direct comparison is represented by a solid line and each
 risk difference (RD) with 95% conﬁdence interval (CI). The values of RD (with 95% CI)
 software, respectively. Symbols: ‘+’indicates which treatment is favored at levels of
ﬁcant difference; ‘t’ indicates which treatment is favored by a trend in cases of no
Fig. 4. Vestibulocerebellar AEs induced by eslicarbazepine acetate, lacosamide and oxcarbazepine in controlled studies. Indirect comparisons (RD (95% IC)) at higher
recommended dosages (ESL: 1200 mg/day, LCM 400 mg/day and OXC 1200 mg/day) (for details, see text and Fig. 2).
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with ESL 1200 mg, LCM 400 mg, and OXC 1200 mg were: 6 [5,9]; 5
[4,6]; 5 [4,10] for dizziness, 19 [10,281]; 13 [9,21]; 5 [4,8] for
ataxia/coordination abnormal, and 15 [9,30]; 12 [9,19]; 4 [3,5] for
diplopia.
4. Discussion
The ﬁrst ﬁnding of this meta-analysis of neurological AEs of ESL,
LCM and OXC, is that there are several AEs for each AED that are
inﬂuenced by dose. In fact, almost all treatment-emergent AEs
were more frequently observed at higher doses. In a previous
meta-analysis of all available randomized controlled trials (also
those performed in patients with other disorders than epilepsy),
we found that LCM treatment was associated with a range of
neurological AEs which were clearly and signiﬁcantly dose-
dependent.5 Recently, adjusted indirect comparisons of each drug
were performed vs the pooled estimate effect of all other AEDs in
three meta-analyses of placebo-controlled studies with some new
AEDs26 or newest AEDs.27,28
Even though equi-effective doses of drugs should ideally be
compared for the assessment of the tolerability pattern of dose-
dependent AEs, unlikely there is no way to establish equi-effective
doses of these AEDs. For all these reasons, we decided to compare
in our meta-analysis only those doses recommended in the
approved SPCs excluding all other doses used in clinical trials.
According to these indications, minimum recommended doses are
800 mg/day for ESL, 200 mg/day for LCM, and 600 mg/day for OXC,
while maximum are 1200 mg/day, 400 mg/day and 1200 mg/day,
for each AED respectively.
Although OXC was also studied at 2400 mg daily and the SPC
mentions this can be an effective dosage, we decided not to include
it as the highest recommended dosage. Firstly, because in the OXC
study a large number of patients were discontinued because of AEs
in the 2400 mg/daily group and a protocol amendment was
prepared to allow for a blinded reduction to 1800 mg/daily either
directly after randomization or on the occurrence of AEs; forty-
seven of the 174 patients randomized to the 2400 mg/daily group
were in fact treated with 1800 mg/daily which in our opinion does
not allow an accurate evaluation of the 2400 mg/daily tolerability
proﬁle. Also of note, 128 (74%) patients in the 2400 mg/daily group
prematurely discontinued treatment, which implies this dose may
not provide the best risk/beneﬁt ratio in clinical practice. Finally, a
recent comparative pharmacokinetic study between ESL and OXC
indicates that a ratio close to 1:1 is probably the best way to
compare these drugs.29
ESL was studied at 400 mg/daily in two trials but in both failed
to show signiﬁcant improvements in seizure control as compared
to placebo and hence the dosage is not recommended in the SPC.11
LCM was studied at 600 mg/daily in two trials but although the
dosage was efﬁcacious the risk/beneﬁt was not considered
favorable and the dosage is not recommended in the SPC.12,13
In our study, we made an indirect comparison of tolerability,
through the analysis of placebo-subtracted percentage of patients
who discontinue because of AEs, and a selected number of AEs:
dizziness, coordination disturbance/ataxia, and diplopia which are
a characteristic expression of vestibulocerebellar involvement.
These neurological AEs are frequently associated with AEDs acting
on voltage-gated sodium channels.
Looking at Figs. 3 and 4, we can see that at higher recommended
doses, OXC caused signiﬁcantly more withdrawals due to AEs and
signiﬁcantly more frequent coordination disturbances/ataxia and
diplopia than ESL and LCM. Analysis of patients with dizziness,
which is a subjective, and probably less speciﬁc sign of
cerebellovestibular involvement, showed only a trend for a better
tolerability of ESL and LCM compared to OXC. These data clearlyindicate that, regarding these dose-dependent AEs, 1200 mg of
OXC has a worse tolerability pattern than 1200 mg/day of ESL and
400 mg/day of LCM. Comparison between ESL and LCM, did not
give signiﬁcant results.
We think that these ﬁndings should be accepted with some
criticism since two factors might have inﬂuenced tolerability of
these AEDs: titration speed and possible differences between the
populations of patients included in the studies. While OXC has
been titrated to 1200 mg/day in only one week, both ESL and LCM
were titrated more slowly to their respective effective recom-
mended daily dosage (1200 mg/day and 400 mg/day). Regarding
the population of patients included, the most important factor is,
perhaps, the number of AEDs assumed by recruited patients. In the
OXC study, up to 3 AEDS were allowed, while 2 studies with ESL
and 1 study with LCM recruited only patients treated with no
more than 2 AEDs (see Appendix 2). These factors may have
contributed to worsen OXC tolerability proﬁle although they
cannot explain these ﬁndings. A further limit in the validity of our
results may be searched in high values of heterogeneity which
were found for some items. In this case the adoption of the random
effect model may have been conservative and have hidden
possible differences.
Regarding quality of studies included in this meta-analysis, we
think that risk of bias is acceptable even though several details on
study procedures were not available. For a description of risk of
bias of such studies, see supplement document n 2. Finally, it has
been hypothesized that tolerability of sodium blockers is worsened
by other coadministered sodium blockers.5 In this meta-analysis,
we think that tolerability of OXC, LCM and ESL, which share a
similar mechanism of action, may had been inﬂuenced in a similar
way by other AEDs.
Why OXC at high recommended doses seems to display a worse
proﬁle than that observed with ESL and LCM? Mechanism of action
of all these AEDs is at the level of voltage-dependent Na+ channels
and it is known that all AEDs with this mechanism of action cause
vestibulocerebellar AEs.3 However, there are differences between
these agents. It has been demonstrated that LCM determine a
selective enhancement of slow inactivation but without apparent
interaction with fast inactivation gating.30
Eslicarbazepine (the main active metabolite of both ESL acetate
and OXC) has also recently shown not to share with carbamazepine
and oxcarbazepine the ability to alter fast inactivation of VGSC, but
rather appears to modify the kinetics and voltage-dependence of
slow inactivation states.29 Furthermore, eslicarbazepine has an
afﬁnity with the resting form of the channel about three times less
than carbamazepine31 and it has been suggested that eslicarba-
zepine is less likely to bind to normally active neurons and less
likely to cause adverse neurological consequences.32
Perhaps, some different kinetic characteristics might better
explain differences in the tolerability proﬁle between these AEDs.
Fluctuations of drug levels in plasma may strongly affect
susceptibility to some AEs.32 It is well known that the traditional
sodium blocker CBZ, mainly in induced subjects, has intermittent
AEs time-locked with peak drug concentrations33 and, for this
reason, a controlled release CBZ formulation is better tolerated in
patients with a short CBZ half-life.34 Although much less data are
available for OXC, also in this case it has been observed that
several dose-dependent neurological AEs such as nystagmus,
sedation, blurred vision, and dizziness occur intermittently
during the day and mainly in the hours following drug
administration.35
The main difference in terms of kinetic properties between ESL
and OXC is that ESL is rapidly converted to eslicarbazepine,31,36
while OXC – with a half-life of 1–2.5 h37 before transformation in
its active metabolite – is detectable in plasma and might per se
determine an effect in the brain. In a recent study performed on
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metabolites in plasma and cerebrospinal ﬂuid, it was observed a
peak concentration of OXC in plasma and cerebrospinal ﬂuid after
OXC but not after ESL administration. Thus, the quick increase of
OXC levels in the brain might explain the occurrence of some time-
locked and intermittent AEs after OXC administration. OXC acts
primarily on fast inactivation VGSC (as mentioned before) and has
a higher afﬁnity with the resting state of the channel as compared
with eslicarbazepine which may explain the occurrence of the
neurological AEs associated with its peak in plasma and CSF.
This was the ﬁrst meta-analysis aimed at comparing some
aspects of tolerability of three AEDs. For a correct interpretation of
our results, some methodological limits should be considered.
First, network meta-analysis allow indirect comparisons between
drugs used for the same indication but it should be kept in mind
the possibility of biases which may be caused mainly by
differences in the population of patients recruited in studies and
also by differences in study protocols. Secondly, we focused our
comparison of these three AEDs only on tolerability while we know
that treatment decisions are made on the balance of effectiveness
and harm and not harm alone. However, we are strongly convinced
that several important methodological aspects – e.g. different ways
to assess responder ratio (some studies considered all double-blind
phase, other studies only maintenance phase), last observation
carried forward (LOCF) analysis, and other aspects which have
been carefully discussed by Rheims et al.38 – limit comparison of
efﬁcacy of AEDs but these aspects do not inﬂuence the analysis of
tolerability.38
In conclusion, all AEDs may cause neurological AEs which can
limit their use and, ultimately, impair success of treatment. In this
meta-analysis we observed that, at higher recommended doses,
ESL and LCM were signiﬁcantly associated with a lower
withdrawal rate due to AEs and a lower percentage of neurological
dose-dependent AEs than OXC.
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